eligibility_summary
Eligible: All ages with MSK-confirmed sarcoma receiving or planned for immune checkpoint inhibitors (anti-PD-1/PD-L1, CTLA-4, LAG-3) alone/with systemic therapy, or ACT (e.g., lifileucil, afamitresgene autoleucel, letetresgene autoleucel), novel checkpoints included. Exclude: refusal to consent to collection of baseline and longitudinal clinicopathologic data.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study type: observational cohort of sarcoma patients receiving immunotherapy in routine care. Interventions captured: 1) Immune checkpoint blockade—monoclonal antibodies against PD-1, PD-L1, CTLA-4, and LAG-3. Mechanism: antibody-mediated blockade of inhibitory receptors/ligands to restore and amplify T‑cell activation, proliferation, and cytotoxic function. 2) Adoptive cell therapy—autologous T cells: tumor-infiltrating lymphocytes (e.g., lifileucil) and engineered T‑cell receptor therapies (e.g., afamitresgene autoleucel targeting MAGE‑A4, letetresgene autoleucel targeting NY‑ESO‑1). Mechanism: infusion of tumor-reactive T cells, TCR-Ts recognize peptide–HLA complexes on tumor cells, mediating targeted killing. Cells/pathways targeted: effector T cells (primarily CD8+), PD‑1/PD‑L1, CTLA‑4, LAG‑3 checkpoints, antigen-presenting interactions, and tumor cells expressing specific antigens (MAGE‑A4, NY‑ESO‑1).